Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab versus dalteparin for cancer-associated venous thromboembolism in gastrointestinal or genitourinary cancer
NL-OMON53552Phase 3Recruiting
- Sponsor
- Anthos Therapeutics
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abelacimab in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Anthos Therapeutics. Primary endpoint: Primary efficacy endpoint. Started Apr 2023; status: recruiting.
02
Drugs
abelacimab
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON53552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53552.